Amgen recently released the full data from a trial involving its GLP-1 drug, MariTide. More than one-quarter of the ...

July kicks off the latter half of 2025, and the first six months of this year have been eventful, to say the least. Yet, the ...

These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...

While Eli Lilly’s LLY top-line continues to touch new sky highs thanks to its blockbuster GLP-1 medicines — Mounjaro (for ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Mayo Clinic also notes that colon cancer symptoms can also present themselves with more frequent diarrhoea or constipation, ...

Issues ranging from medicine approval delays to attacks on Harvard research grants knock driver of regional economy ...

For the first of these tasks Dr Baker and his colleagues use RF diffusion, an AI model they have developed to predict a ...

For CVS Health CVS, the key to building customer trust is to enhance access to life-changing medications and also make them affordable. Beginning July 1, the company’s Pharmacy Benefit Manager (“PBM”) ...

Lantheus Holdings offers a compelling bull case, with PYLARIFY and DEFINITY driving valuation and strong growth prospects.

Research presented at the ASCO Annual Meeting 2025 highlighted potential new standards of care and other advances in ...

Once-weekly efsitora vs once-daily degludec was associated with comparable glycemic control outcomes and improved ...